Molecular Testing Reshapes How Doctors Diagnose Unexplained Low Blood Counts
New guidance on using clonal hematopoiesis markers and inherited syndrome testing to evaluate cytopenias and bone marrow failure.
Summary
Cytopenias—abnormally low blood cell counts—are increasingly understood through molecular testing that detects clonal hematopoiesis and inherited bone marrow failure syndromes (IBMFS). Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of uncertain significance (CCUS) represent premalignant states where somatic myeloid mutations drive risk. Prognostication tools like the Clonal Hematopoiesis Risk Score, MN-predict, and Clonal Cytopenia Risk Score help stratify patients by malignant transformation risk, influenced by mutation type, variant allele frequency, and exposures like chemotherapy or smoking. For suspected IBMFS, telomere length testing and chromosomal breakage analysis plus comprehensive germline sequencing guide diagnosis. Confirmed IBMFS patients face risks of multi-organ dysfunction and malignancy, often warranting stem cell transplantation evaluation.
Detailed Summary
Unexplained cytopenias—reductions in red cells, white cells, or platelets—are common in adults and increasingly linked to molecular abnormalities detectable through modern genomic testing. This educational review from The Ohio State University, published in Hematology: ASH Education Program 2025, synthesizes current knowledge on how clinicians should approach cytopenia workup through a molecular lens, with particular focus on clonal hematopoiesis and inherited bone marrow failure syndromes.
Clonal hematopoiesis (CH) represents a spectrum of premalignant states characterized by somatic mutations in myeloid driver genes arising in hematopoietic stem cells. When CH occurs without overt cytopenia or dysplasia meeting diagnostic thresholds for myelodysplastic syndrome (MDS) or other myeloid neoplasms, it is termed CHIP. When cytopenias are present but criteria for MDS are not met, the condition is classified as CCUS—a higher-risk entity. Key factors determining malignant progression risk include the specific mutation involved (e.g., splicing factor mutations carry higher risk), the number of concurrent mutations, and the variant allele frequency (VAF), with higher VAF indicating a larger clonal burden.
Three prognostication frameworks are highlighted: the Clonal Hematopoiesis Risk Score, MN-predict, and the Clonal Cytopenia Risk Score. These tools integrate mutation profiles, VAF, and clinical variables to estimate the probability of progression to overt myeloid neoplasm, helping clinicians decide on surveillance intensity and intervention timing. Environmental and iatrogenic exposures—including prior chemotherapy, radiation therapy, and cigarette smoking—can accelerate clonal evolution and should be factored into risk assessment.
For patients in whom IBMFS is suspected, the diagnostic algorithm differs substantially. Telomere length testing is essential for diagnosing dyskeratosis congenita and related telomeropathies, while chromosomal breakage analysis (using diepoxybutane or mitomycin C) remains the gold standard for Fanconi anemia. Comprehensive germline sequencing panels can identify causative mutations in genes associated with Diamond-Blackfan anemia, Shwachman-Diamond syndrome, and other rare syndromes. Importantly, IBMFS may present in adults without classic syndromic features, making molecular screening valuable even in the absence of obvious extrahematopoietic findings.
Once IBMFS is confirmed, patients require syndrome-specific surveillance given elevated risks of solid tumors, leukemia, pulmonary fibrosis, liver disease, and other organ complications. Allogeneic hematopoietic stem cell transplantation (HSCT) may be indicated for severe bone marrow failure or high malignant risk, though conditioning regimen modifications are often necessary due to underlying DNA repair deficiencies. The review underscores the need for multidisciplinary management and early genetics consultation in these complex cases.
Key Findings
- CCUS carries higher malignant progression risk than CHIP; mutation type, VAF, and mutation count all influence prognosis.
- Three scoring tools—Clonal Hematopoiesis Risk Score, MN-predict, Clonal Cytopenia Risk Score—stratify myeloid neoplasm progression risk.
- Chemotherapy, radiation, and smoking accelerate clonal evolution and must be considered in risk stratification.
- Telomere length testing and chromosomal breakage analysis are first-line for suspected IBMFS; germline sequencing confirms diagnosis.
- IBMFS patients face multi-organ risks and often require modified HSCT conditioning due to DNA repair defects.
Methodology
This is a narrative educational review article published in the ASH Education Program, synthesizing current evidence on molecular diagnostics for cytopenia and bone marrow failure. It is not a primary research study; no original patient data, experimental cohorts, or statistical analyses were performed. The authors integrate published scoring systems, diagnostic algorithms, and clinical guidelines to provide practical guidance.
Study Limitations
As a review article, conclusions are based on synthesis of existing literature rather than new primary data, limiting direct evidence grading. The prognostication tools described have variable validation across diverse patient populations. The paper's full text was not accessible in XML form, so some specific details may be incompletely captured from the abstract and metadata alone.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.